 |
|
Title: Department of Veterans' Affairs Rehabilitation Research and Development Technology Transfer Program
Author: Saleem Sheredos
Published: 1999
Publication: Assistive Technology Transfer Update: Vol. 1 Issue 1 (Spring)
|
A large part of successful technology application relies
primarily on effective mechanisms that help bring emerging research and
development (R&D) prototypes from the lab into the commercial market. The
mission of the Veterans' Affairs Rehabilitation Research and Development (VA
Rehab R&D) Service is to support an intramural R&D program for improving the
quality of life of veterans with disabilities. The mission is accomplished
through funding of R&D proposals that will improve the treatment and
rehabilitation of veterans within the following priority areas:
prosthetics/amputation/orthotics; spinal cord injury (and other neuromuscular
disorders); sensory/cognitive/communication aids; and aging. Requests
involving non-VA-funded developments are also reviewed to identify those that
may meet specific VA needs within these priority areas. In order to support
this mission and provide effective transfer of promising developments for
commercial production and clinical application, the VA Rehab R&D Service
established the Technology Transfer Section (TTS).
The TTS is directly responsible for the design and
management of a pro-active process to validate proven rehab R&D findings and
progressing successful outcomes into clinical use, manufacture, and
commercial availability. Its approach is based on the premise that tech
transfer should begin when a developer moves from concept to tangible working
model. The ultimate goal is for timely transition of prototype developments
into commercially viable products and techniques that have a concomitant
benefit for veterans and the public.
The TTS employs a consumer-driven cycle that provides
resources to: accomplish manufacture of pre-commercial models; conduct
national clinical evaluation studies to validate the development's success
in meeting an identified need; secure a manufacturer at the onset; and
define readiness for commercial availability and production. Limited or
unproved rehab market demand and product salability can often deter potential
manufacturers from supporting commercial production and distribution. The
procurement of pre-commercial models for evaluation purposes serves two
objectives: as a conduit for consumer feedback, product performance,
commercial readiness, and clinical guidelines, and as a barometer for
potential market size, demand, and target population. Fostering synergetic
efforts between developer, manufacturer, consumer, and federal funding
sources is important to help build a solid foundation for successful
technology transfer.
[ Top of Page ]
|
 |